FY2024 Earnings Estimate for CRSP Issued By William Blair

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin forecasts that the company will earn ($4.66) per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.17) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($1.03) EPS, Q2 2025 earnings at ($0.97) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.38) EPS and FY2025 earnings at ($3.31) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the business posted ($1.41) earnings per share.

CRSP has been the subject of a number of other research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Chardan Capital restated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $77.93.

CRISPR Therapeutics Stock Down 1.8 %

Shares of CRISPR Therapeutics stock opened at $47.78 on Wednesday. The firm has a market capitalization of $4.08 billion, a P/E ratio of -16.88 and a beta of 1.62. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10. The company has a 50 day moving average price of $48.82 and a 200 day moving average price of $51.33.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 1.86 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Larson Financial Group LLC raised its holdings in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares during the last quarter. GPS Wealth Strategies Group LLC lifted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in CRISPR Therapeutics during the second quarter worth $35,000. Denver PWM LLC purchased a new stake in CRISPR Therapeutics in the 2nd quarter valued at $45,000. Finally, National Bank of Canada FI increased its stake in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.